Methods of delivering a pseudotyped lentivirus
US-10266847-B2 · Apr 23, 2019 · US
Packaging cell for making a pseudotyped lentivirus
US10696984B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10696984-B2 |
| Application number | US-201916293151-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2019 |
| Priority date | Jul 21, 2006 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated packaging cell comprising: (a) a replication defective lentiviral vector comprising an exogenous polynucleotide of interest; (b) a vector encoding a modified alphavirus E2 glycoprotein that specifically binds DC-SIGN; and (c) at least one plasmid encoding proteins required for lentiviral particle packaging, wherein the packaging cell is capable of producing a replication defective lentivirus pseudotyped with a virus envelope comprising the modified alphavirus E2 glycoprotein, and wherein the pseudotyped replication deficient lentivirus has increased efficiency in transducing dendritic cells expressing DC-SIGN relative to cell types not expressing DC-SIGN. 2. The packaging cell of claim 1 , wherein the packaging cell is a 293 or 293T cell. 3. The packaging cell of claim 1 , wherein the replication defective lentiviral vector comprises a self-inactivating 3′ LTR. 4. The packaging cell of claim 1 , wherein the E2 alphavirus glycoprotein comprises the amino acid sequence of SEQ ID NO: 11. 5. The packaging cell of claim 1 , wherein the polynucleotide of interest encodes an antigen selected from the group consisting of a viral antigen, an HIV antigen, an HSV antigen, and a tumor antigen. 6. The packaging cell of claim 5 , wherein the antigen comprises a gag protein. 7. A culture comprising a plurality of packaging cells of claim 1 . 8. A culture comprising a plurality of packaging cells of claim 5 .
Assignees
Inventors
Classifications
Retroviral vectors · CPC title
Viral antigens · CPC title
- C12N15/86Primary
Viral vectors · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Special targeting system for viral vectors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10696984B2 cover?
- Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
- Who is the assignee on this patent?
- California Inst Of Techn
- What technology area does this patent fall under?
- Primary CPC classification C12N15/86. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).